Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 4—April 2014
CME ACTIVITY - Research

Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009

Russell S. Barlow, Emilio E. DeBessComments to Author , Kevin L. Winthrop, Jodi A. Lapidus, Robert Vega, and Paul R. Cieslak
Author affiliations: Oregon Health Authority, Portland, Oregon USA (R.S. Barlow, E.E. DeBess, P.R. Cieslak); Oregon Health and Science University, Portland (R.S. Barlow, K.L. Winthrop, J.A. Lapidus); Oregon State Public Health Lab, Hillsboro, Oregon, USA (R. Vega)

Main Article

Table 4

Unadjusted associations of CIR of Salmonella isolates among 1,813 patients, by travel destination, Oregon, 2004–2009*

Destination No. patients % CIR isolates Odds ratio (95% CI)
None 1,571 16.8 Referent
Mexico 119 9.2 0.5 (0.3–1.0)
Southeast Asia 29 41.4 3.5 (1.7–7.4)
Europe 25 16.0 0.9 (0.3–2.8)
East Asia 17 35.3 2.7 (1.0–7.4)
Caribbean 16 12.5 0.7 (0.2–3.1)
Central America† 16 6.3 0.3 (0.1–2.5)
Africa 10 20.0 1.2 (0.3–5.9)
Oceania 5 20.0 1.2 (0.1–11.1)
Canada 5 40.0 3.3 (0.5–19.8)
Any travel 242 16.9 1.0 (0.7–1.4)

*CIR, clinically important resistance to >1 of the following: ampicillin, ceftriaxone, ciprofloxacin, gentamicin, or trimethoprim/sulfamethoxazole. Boldface indicates statistical significance at p<0.05.
†Excludes Mexico.

Main Article

Page created: March 18, 2014
Page updated: March 18, 2014
Page reviewed: March 18, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external